These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 16251299

  • 1. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y.
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [Abstract] [Full Text] [Related]

  • 2. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [Abstract] [Full Text] [Related]

  • 3. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, Iizawa Y, Baba M.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K, Baba M.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [Abstract] [Full Text] [Related]

  • 5. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M, Aikawa K, Miyamoto N, Aramaki Y, Kanzaki N, Takashima K, Kuze Y, Iizawa Y, Baba M, Shiraishi M.
    J Med Chem; 2006 Mar 23; 49(6):2037-48. PubMed ID: 16539392
    [Abstract] [Full Text] [Related]

  • 6. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM, Wang ZX, Trent JO, Murray JL, Hu QX, DeLeeuw L, Moore PS, Chang Y, Peiper SC.
    J Mol Biol; 2001 Nov 09; 313(5):1181-93. PubMed ID: 11700073
    [Abstract] [Full Text] [Related]

  • 7. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
    Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B.
    Nature; 1996 Aug 29; 382(6594):833-5. PubMed ID: 8752281
    [Abstract] [Full Text] [Related]

  • 8. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M.
    Proc Natl Acad Sci U S A; 1999 May 11; 96(10):5698-703. PubMed ID: 10318947
    [Abstract] [Full Text] [Related]

  • 9. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP.
    Virology; 2005 Jul 20; 338(1):182-99. PubMed ID: 15935415
    [Abstract] [Full Text] [Related]

  • 10. I-TAC/CXCL11 is a natural antagonist for CCR5.
    Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B.
    J Leukoc Biol; 2004 Sep 20; 76(3):701-8. PubMed ID: 15178708
    [Abstract] [Full Text] [Related]

  • 11. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
    Wang FY, He SY, Zhang ZJ, He LF, Chen XW, Teng T.
    AIDS Res Hum Retroviruses; 2011 Oct 20; 27(10):1111-5. PubMed ID: 21375388
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological characterization of the chemokine receptor, CCR5.
    Mueller A, Mahmoud NG, Goedecke MC, McKeating JA, Strange PG.
    Br J Pharmacol; 2002 Feb 20; 135(4):1033-43. PubMed ID: 11861332
    [Abstract] [Full Text] [Related]

  • 13. Monocyte chemoattractant protein-2 (CC chemokine ligand 8) inhibits replication of human immunodeficiency virus type 1 via CC chemokine receptor 5.
    Yang OO, Garcia-Zepeda EA, Walker BD, Luster AD.
    J Infect Dis; 2002 Apr 15; 185(8):1174-8. PubMed ID: 11930329
    [Abstract] [Full Text] [Related]

  • 14. A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.
    Blanpain C, Buser R, Power CA, Edgerton M, Buchanan C, Mack M, Simmons G, Clapham PR, Parmentier M, Proudfoot AE.
    J Leukoc Biol; 2001 Jun 15; 69(6):977-85. PubMed ID: 11404385
    [Abstract] [Full Text] [Related]

  • 15. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.
    van Wanrooij EJ, Happé H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, Kuiper J.
    Arterioscler Thromb Vasc Biol; 2005 Dec 15; 25(12):2642-7. PubMed ID: 16239591
    [Abstract] [Full Text] [Related]

  • 16. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
    Aquaro S, Menten P, Struyf S, Proost P, Van Damme J, De Clercq E, Schols D.
    J Virol; 2001 May 15; 75(9):4402-6. PubMed ID: 11287590
    [Abstract] [Full Text] [Related]

  • 17. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M.
    Antimicrob Agents Chemother; 2005 Nov 15; 49(11):4721-32. PubMed ID: 16251317
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K, Hatse S, Vermeire K, Aquaro S, De Clercq E, Gerlach LO, Rosenkilde M, Schwartz TW, Skerlj R, Bridger G, Schols D.
    J Virol; 2004 Dec 15; 78(23):12996-3006. PubMed ID: 15542651
    [Abstract] [Full Text] [Related]

  • 19. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.
    Tremblay CL, Giguel F, Guan Y, Chou TC, Takashima K, Hirsch MS.
    Antimicrob Agents Chemother; 2005 Aug 15; 49(8):3483-5. PubMed ID: 16048964
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5).
    Elliott MB, Tebbey PW, Pryharski KS, Scheuer CA, Laughlin TS, Hancock GE.
    J Med Virol; 2004 Jun 15; 73(2):300-8. PubMed ID: 15122808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.